• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

美沙拉嗪诱发溃疡性结肠炎加重。

Mesalazine induced exacerbation of ulcerative colitis.

作者信息

Kapur K C, Williams G T, Allison M C

机构信息

Department of Gastroenterology, Royal Gwent Hospital, Newport.

出版信息

Gut. 1995 Dec;37(6):838-9. doi: 10.1136/gut.37.6.838.

DOI:10.1136/gut.37.6.838
PMID:8537058
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC1382949/
Abstract

5-Aminosalicylic acid (5-ASA) compounds occasionally exacerbate diarrhoea in patients with inflammatory bowel disease. This is thought to be due to a secretory mechanism in most cases. A patient with presumed intolerance to sulphasalazine and 5-ASA preparations who developed endoscopic and histological evidence of disease relapse after a rectal challenge with mesalazine is reported.

摘要

5-氨基水杨酸（5-ASA）化合物偶尔会使炎症性肠病患者的腹泻加重。在大多数情况下，这被认为是由于一种分泌机制。本文报告了一名推测对柳氮磺胺吡啶和5-ASA制剂不耐受的患者，在用美沙拉嗪进行直肠激发试验后出现了疾病复发的内镜和组织学证据。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/4665/1382949/cd55606c8c5f/gut00531-0117-a.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/4665/1382949/cd55606c8c5f/gut00531-0117-a.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/4665/1382949/cd55606c8c5f/gut00531-0117-a.jpg

相似文献

1
Mesalazine induced exacerbation of ulcerative colitis.美沙拉嗪诱发溃疡性结肠炎加重。
Gut. 1995 Dec;37(6):838-9. doi: 10.1136/gut.37.6.838.
2
Salicylate induced exacerbation of ulcerative colitis.水杨酸盐诱发溃疡性结肠炎加重。
Gut. 1987 May;28(5):613-5. doi: 10.1136/gut.28.5.613.
3
Low dose balsalazide (1.5 g twice daily) and mesalazine (0.5 g three times daily) maintained remission of ulcerative colitis but high dose balsalazide (3.0 g twice daily) was superior in preventing relapses.低剂量巴柳氮（每日两次，每次1.5克）和美沙拉嗪（每日三次，每次0.5克）可维持溃疡性结肠炎的缓解，但高剂量巴柳氮（每日两次，每次3.0克）在预防复发方面更具优势。
Gut. 2001 Dec;49(6):783-9. doi: 10.1136/gut.49.6.783.
4
The systemic load and efficient delivery of active 5-aminosalicylic acid in patients with ulcerative colitis on treatment with olsalazine or mesalazine.奥沙拉嗪或美沙拉嗪治疗的溃疡性结肠炎患者中活性5-氨基水杨酸的全身负荷及有效递送情况。
Aliment Pharmacol Ther. 1999 Mar;13(3):357-61. doi: 10.1046/j.1365-2036.1999.00483.x.
5
Nephrotic syndrome from 5-ASA for ulcerative colitis? Complicated by carcinoma of the colon and sclerosing cholangitis.溃疡性结肠炎使用5-氨基水杨酸导致肾病综合征？并发结肠癌和硬化性胆管炎。
J Clin Gastroenterol. 1997 Jan;24(1):37-9. doi: 10.1097/00004836-199701000-00008.
6
Systemic levels of free 5-aminosalicylic acid depend on the nature of the 5-aminosalicyclic acid derivative and not on disease activity or extent in patients with inflammatory bowel disease.游离5-氨基水杨酸的全身水平取决于5-氨基水杨酸衍生物的性质，而非炎症性肠病患者的疾病活动度或病变范围。
Ir J Med Sci. 1999 Oct-Dec;168(4):228-32. doi: 10.1007/BF02944345.
7
Comparison of delayed release 5 aminosalicylic acid (mesalazine) and sulphasalazine in the treatment of mild to moderate ulcerative colitis relapse.延迟释放型5-氨基水杨酸（美沙拉嗪）与柳氮磺胺吡啶治疗轻至中度溃疡性结肠炎复发的比较。
Gut. 1988 May;29(5):669-74. doi: 10.1136/gut.29.5.669.
8
Review article: new developments in the use of 5-aminosalicylic acid in patients with inflammatory bowel disease.综述文章：5-氨基水杨酸在炎症性肠病患者中的应用新进展
Aliment Pharmacol Ther. 1991 Oct;5(5):449-70. doi: 10.1111/j.1365-2036.1991.tb00515.x.
9
[Ulcerative colitis and pericarditis. The role of mesalazine hypersensitivity].
Rev Med Suisse Romande. 1995 Nov;115(11):935-8.
10
Mesalazine induced interstitial nephritis.
Gut. 1994 Oct;35(10):1493-6. doi: 10.1136/gut.35.10.1493.

引用本文的文献

1
Day-by-Day Management of the Inpatient With Moderate to Severe Inflammatory Bowel Disease.中重度炎症性肠病住院患者的每日管理
Gastroenterol Hepatol (N Y). 2020 Sep;16(9):449-457.
2
Stopping 5-aminosalicylates in patients with ulcerative colitis starting biologic therapy does not increase the risk of adverse clinical outcomes: analysis of two nationwide population-based cohorts.在开始使用生物疗法的溃疡性结肠炎患者中停用 5-氨基水杨酸不会增加不良临床结局的风险：两项全国性基于人群队列的分析。
Gut. 2019 Jun;68(6):977-984. doi: 10.1136/gutjnl-2018-317021. Epub 2018 Nov 12.
3
Crohn's Disease with Mesalazine Allergy that Was Difficult to Differentiate from Comorbid Ulcerative Colitis.

本文引用的文献

1
Side effects of nonsteroidal anti-inflammatory drugs on the small and large intestine in humans.非甾体抗炎药对人体小肠和大肠的副作用。
Gastroenterology. 1993 Jun;104(6):1832-47. doi: 10.1016/0016-5085(93)90667-2.
2
Effect of olsalazine and mesalazine on human ileal and colonic (Na+ + K+)-ATPase. A possible diarrhogenic factor?奥沙拉嗪和美沙拉嗪对人回肠及结肠（钠+钾）-ATP酶的作用。一个可能的致腹泻因素？
Clin Investig. 1993 Apr;71(4):286-9. doi: 10.1007/BF00184728.
3
Analgesic ingestion and other factors preceding relapse in ulcerative colitis.
患有美沙拉嗪过敏的克罗恩病，难以与合并的溃疡性结肠炎相鉴别。
Intern Med. 2019 Mar 1;58(5):649-654. doi: 10.2169/internalmedicine.1607-18. Epub 2018 Oct 17.
4
5-Aminosalicylic acid aggravates colitis mimicking exacerbation of ulcerative colitis.5-氨基水杨酸会加重模拟溃疡性结肠炎发作的结肠炎。
Intest Res. 2018 Oct;16(4):635-640. doi: 10.5217/ir.2018.00015. Epub 2018 Oct 10.
5
A Case of Right-Sided Ulcerative Colitis with Mesalamine-Induced Hypersensitivity Reactions.1例右侧溃疡性结肠炎伴美沙拉嗪诱导的超敏反应
Am J Case Rep. 2018 May 31;19:623-629. doi: 10.12659/AJCR.909644.
6
Management of inflammatory bowel disease in older persons: evolving paradigms.老年人炎症性肠病的管理：不断演变的模式
Intest Res. 2018 Apr;16(2):194-208. doi: 10.5217/ir.2018.16.2.194. Epub 2018 Apr 30.
7
Elderly patients and inflammatory bowel disease.老年患者与炎症性肠病。
World J Gastrointest Pharmacol Ther. 2016 Feb 6;7(1):51-65. doi: 10.4292/wjgpt.v7.i1.51.
8
Severe and Rapid Progression in Very Early-Onset Chronic Granulomatous Disease-Associated Colitis.
J Clin Immunol. 2015 Aug;35(6):583-8. doi: 10.1007/s10875-015-0180-2. Epub 2015 Aug 2.
9
Mesalamine treatment mimicking relapse in a child with ulcerative colitis.美沙拉嗪治疗模仿儿童溃疡性结肠炎的复发。
World J Pediatr. 2014 Nov;10(4):371-3. doi: 10.1007/s12519-014-0485-x. Epub 2014 Jun 28.
10
Medical management of ulcerative colitis with a specific focus on 5-aminosalicylates.溃疡性结肠炎的药物治疗，特别关注5-氨基水杨酸类药物。
Clin Med Insights Gastroenterol. 2012 Oct 18;5:77-83. doi: 10.4137/CGast.S8673. eCollection 2012.
溃疡性结肠炎复发前的镇痛剂摄入及其他因素。
Gut. 1983 Mar;24(3):187-9. doi: 10.1136/gut.24.3.187.
4
Acute ulcerative colitis--a rare complication of sulfasalazine therapy.
Hepatogastroenterology. 1984 Aug;31(4):192-3.
5
Exacerbation of diarrhoea and pain in patients treated with 5-aminosalicylic acid for ulcerative colitis.溃疡性结肠炎患者使用5-氨基水杨酸治疗后腹泻和疼痛加剧。
Lancet. 1984 Apr 21;1(8382):917-8. doi: 10.1016/s0140-6736(84)91386-2.
6
Sulfasalazine-induced exacerbation of ulcerative colitis.柳氮磺胺吡啶诱发的溃疡性结肠炎加重
N Engl J Med. 1982 Feb 18;306(7):409-12. doi: 10.1056/NEJM198202183060708.
7
Relapse of ulcerative proctocolitis during treatment with non-steroidal anti-inflammatory drugs.非甾体抗炎药治疗期间溃疡性直肠结肠炎的复发
Postgrad Med J. 1981 May;57(667):297-9. doi: 10.1136/pgmj.57.667.297.
8
Salicylate induced exacerbation of ulcerative colitis.水杨酸盐诱发溃疡性结肠炎加重。
Gut. 1987 May;28(5):613-5. doi: 10.1136/gut.28.5.613.
9
Adverse effects with oral 5-aminosalicyclic acid.口服5-氨基水杨酸的不良反应。
J Clin Gastroenterol. 1988 Dec;10(6):635-7. doi: 10.1097/00004836-198812000-00012.
10
Clinical experience of the tolerance of mesalazine and olsalazine in patients intolerant of sulphasalazine.
Scand J Gastroenterol. 1987 Apr;22(3):332-6. doi: 10.3109/00365528709078600.